Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Second-line antituberculous therapy

INTRODUCTION

In general, first-line treatment of tuberculosis (TB) consists of combination therapy with isoniazid, rifampin (rifapentine and rifabutin under specific situations), pyrazinamide, and ethambutol. In the setting of drug resistance or intolerance to first-line agents, second-line agents may be used (table 1). These include fluoroquinolones, injectable agents, and less effective agents or drugs for which clinical data are sparse.

The second-line antituberculous drugs are so classified because of relative lack of clinical data, unfavorable or poorly characterized pharmacokinetic profile, and/or increased incidence and severity of adverse events (table 2) [1,2]. Experience with some of these agents is increasing, based upon the need for alternative therapies for treatment of drug-resistant TB.

This topic will review pharmacologic issues related to use of second-line antituberculous drugs, with the exception of the fluoroquinolones and aminoglycosides (other than streptomycin); these are discussed separately. (See "Fluoroquinolones" and "Aminoglycosides".)

The clinical approaches to treatment of tuberculosis and drug-resistant tuberculosis are discussed separately. (See "Treatment of pulmonary tuberculosis in HIV-negative patients" and "Treatment of pulmonary tuberculosis in the HIV-infected patient" and "Diagnosis, treatment, and prevention of drug-resistant tuberculosis", section on 'Clinical approach'.)

INDICATIONS FOR USE

There are two major indications for the use of second-line therapy in the treatment of tuberculosis: resistance of the M. tuberculosis isolate to first-line agents and/or patient intolerance (including hypersensitivity reactions) to first-line drugs.

                                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Apr 14, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.
  2. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77:1253.
  3. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621.
  4. United States Pharmacopeial Dispensing Information. Drug Information for the Health Care Professional, Micromedex, Englewood, CO 1999. Vol Vol I, p.69.
  5. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996; 274:1367.
  6. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43:727.
  7. Nanavaty J, Mortensen JE, Shryock TR. The effects of environmental conditions on the in vitro activity of selected antimicrobial agents against Escherichia coli. Curr Microbiol 1998; 36:212.
  8. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8:496.
  9. Meier A, Sander P, Schaper KJ, et al. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40:2452.
  10. Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994; 38:238.
  11. ROBINSON GC, CAMBON KG. HEARING LOSS IN INFANTS OF TUBERCULOUS MOTHERS TREATED WITH STREPTOMYCIN DURING PREGNANCY. N Engl J Med 1964; 271:949.
  12. CONWAY N, BIRT BD. STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR. Br Med J 1965; 2:260.
  13. Quémard A, Lanéelle G, Lacave C. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob Agents Chemother 1992; 36:1316.
  14. Vannelli TA, Dykman A, Ortiz de Montellano PR. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 2002; 277:12824.
  15. Winder FG. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the Mycobacteria, Academic Press Inc, New York 1982.
  16. Aminosalicylate sodium. In: Drug Facts and Comparisons, 4th ed, St. Louis 2000. p.750.
  17. Peloquin CA, Berning SE, Huitt GA, et al. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999; 159:932.
  18. Peloquin CA, Henshaw TL, Huitt GA, et al. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994; 14:40.
  19. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013; 62:1.
  20. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf (Accessed on April 01, 2014).
  21. Sirturo (bedaquiline) [table package insert]. Titusville, NJ: Janssen Therapeutics; 2013.